Merck Beats Profit Goals on Strong Cancer Drug Sales
Merck raised its profit outlook after strong sales of its top cancer treatment Keytruda.
Merck is winning big in the fight against cancer. The drug giant posted higher sales than Wall Street expected this quarter. Patients rely on its flagship treatments, and that demand keeps cash flowing into the business.
The star of the report is Keytruda. This top cancer medicine beat sales targets again. Merck also rolled out a new injectable form of the drug. Doctors like this new version because it helps patients get treatment faster.
Because of this success, Merck raised its full-year profit outlook. The company now expects to bring in more money than it planned earlier this year. Strong demand for its core medicine shields the firm from wider market swings.
For everyday investors, Merck shows how a single winning product can anchor a giant company. Healthcare remains a steady place to put money to work when times get choppy.
Source: CNBC
More from Biotech
